Soleno Therapeutics, Inc. (SLNO)
Pre-market: 04:11AM EDT
| Previous close | 0.7830 |
| Open | 0.7800 |
| Bid | 0.0000 x 900 |
| Ask | 0.0000 x 1800 |
| Day's range | 0.7560 - 0.8110 |
| 52-week range | 0.7560 - 3.3600 |
| Volume | 408,533 |
| Avg. volume | 379,910 |
| Market cap | 63.887M |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3930 |
| Earnings date | 08 Nov 2021 - 12 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.00 |
- GlobeNewswire
Soleno Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
REDWOOD CITY, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 2:40 PM Eastern Time. A live audio webcast and replay of the presentation will be ava
- GlobeNewswire
Soleno Therapeutics to Participate in the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
REDWOOD CITY, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on Monday, September 20, 2021 at 1:15 PM Eastern Time. A live audio webcast and replay of the presentation wil
- GlobeNewswire
Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of PWS following One Year Treatment with DCCR
Figure 1 Change from Pre-DCCR HQ-CT Total Score After 13, 26, 39, and 52 Weeks Figure 2 Change in HQ-CT after 26 Weeks and 52 Weeks for DCCR Compared to PfPWS Statistically significant reduction in hyperphagia and all other PWS behavioral parameters in Study C602 Statistically significant improvements compared to natural history of PWS from the PATH for PWS Study On track for data submission to the FDA in Q3 2021 REDWOOD CITY, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc.
